FDA Drug information
Pradaxa
Up to date, easily accessible information about drugs approved by the US Food & Drug Administration (FDA)
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 110 mg/1 Boehringer Ingelheim Pharmaceuticals Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 110 mg/1 Boehringer Ingelheim Pharmaceuticals, Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 150 mg/1 Boehringer Ingelheim Pharmaceuticals Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 150 mg/1 Boehringer Ingelheim Pharmaceuticals, Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 20 mg/1 Boehringer Ingelheim Pharmaceuticals, Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 30 mg/1 Boehringer Ingelheim Pharmaceuticals, Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 40 mg/1 Boehringer Ingelheim Pharmaceuticals, Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 50 mg/1 Boehringer Ingelheim Pharmaceuticals, Inc.
- Pradaxa DABIGATRAN ETEXILATE MESYLATE 75 mg/1 Boehringer Ingelheim Pharmaceuticals Inc.
Learning Zones
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.